Fig. 2: HPV16 antibody avidity over time, stratified by number of HPV vaccine doses received and HPV16 serostatus at time of initial HPV vaccination. | npj Vaccines

Fig. 2: HPV16 antibody avidity over time, stratified by number of HPV vaccine doses received and HPV16 serostatus at time of initial HPV vaccination.

From: HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

Fig. 2

HPV16-seronegative status at first HPV vaccination is represented by the solid line and HPV16 seropositive at first HPV vaccination is represented by the dashed line. Dots represent the geometric mean antibody avidity index for the one-dose group (a) and the three-dose group (b) and the error bars represent 95% confidence intervals (CI). Regression lines are estimated by regressing log(avidity) on either an intercept, an indicator for the second study visit, and/or study year, and reporting on the parameter the parameter 100(eβ-1).

Back to article page